Lupus Science and Medicine Podcast
The Lupus Science & Medicine Podcast provides updates on lupus and related diseases, featuring interviews with researchers, authors, and experts. Episodes focus on new advances in lupus research, treatments, and clinical knowledge. It is tied to the international journal Lupus Science & Medicine, published by BMJ Group and the Lupus Foundation of America. The show is hosted by Dr Anna Wolska and is intended for educational purposes rather than as medical advice.
Episodes
Making Sense of Severe Lupus: How the SLE-DAS Tool Could Improve Care Outcomes
In this episode of the Lupus Foundation of America podcast, Jaren Crump sits down with Dr. Luís Inês, rheumatologist and President of the European Lupus Society, about new research that could change how doctors understand and treat severe lupus. Dr. Inês explains how an evaluation tool known as SLE-DAS, makes it easier for clinicians to measure severe lupus disease activity — and why that matters
Inside Lupus: The Potential of Genetic Endotypes to Personalize Lupus Care
In this episode of the Lupus Science and Medicine Podcast, host Dr. Anna Wolska speaks with Dr. Amerie Grammer about how genetic breakthroughs are paving the way for personalized lupus care. Researchers have identified distinct “genetic endotypes,” patterns of gene activity that explain why lupus affects people differently, including symptoms like kidney disease. These insights could one day enabl
Empowering Lupus Patients: A Treatment Measure Shaped by Their Voices
In this podcast, Dr. Anna Wolska sits down with Dr. Eric Morand to discuss a groundbreaking effort to improve how lupus treatment success is measured in clinical trials. Dr. Morand explains why existing tools weren’t designed for tracking treatment response and describes a rigorous, patient-inclusive Delphi process that narrowed dozens of possible disease aspects down to eight meaningful domains.
Steroid Use for the Treatment of Lupus Nephritis
Lupus nephritis, affecting nearly half of lupus patients, can cause severe kidney damage. Traditionally, high-dose glucocorticoids (~1 mg per kg prednisone) have been used despite significant side effects. In this episode, host Anna Wolska speaks with Dr. Amit Saxena, a rheumatologist and Associate Professor at NYU Langone Health, about his recent research on the use of glucocorticoids in treating
Validating Claims Algorithms for SLE: Geospatial Insights and Impacts on Health Disparities
Join Dr. Anna Wolska from the Lupus Foundation of America as she talks with Dr. Jim Oates about his recently published study in Lupus Science & Medicine on validating claims-based algorithms in Medicare data to identify SLE and lupus nephritis. Dr. Oates explains how ICD-10 coding and geospatial analysis (via the Lupus Index) can help pinpoint disparities, guide clinical trial recruitment, and
Rethinking Lupus Nephritis Treatment: Voclosporin vs. High-Dose Steroids
Early reduction in proteinuria is a key predictor of improved long-term kidney health in lupus nephritis (LN). In this episode, Dr. Anna Wolska from the Lupus Foundation of America speaks with Drs. Maria Dall'Era and Anca Askanase about a new propensity analysis comparing voclosporin-based triple immunosuppressive therapy to traditional high-dose glucocorticoid regimens. They discuss findings from
Rituximab in Childhood Lupus: Insights and Safety
Join Dr. Anna Wolska and Dr. Jordan Roberts, a pediatric rheumatologist, as they explore the use of Rituximab in treating childhood-onset systemic lupus erythematosus (SLE). They discuss key factors for healthcare providers when prescribing Rituximab to children and adolescents, especially for severe cases like lupus nephritis and CNS involvement. Dr. Roberts presents recent research on Rituximab’
Managing Pregnancy in Lupus: Contraception Use and Beyond
In this episode of the Lupus Science and Medicine podcast, Dr. Megan Clowse, a rheumatologist at Duke University, discusses her research on contraceptive practices in women with lupus. Drawing from the RISE Registry, Dr. Clowse explores the alignment of contraception use with 2020 ACR guidelines, uncovering gaps in documentation and prescription practices. The conversation highlights the importanc
Leveraging Positive Psychosocial Factors to Manage Stress in Lupus
Join host Dr. Anna Wolska as she explores a new study in Lupus Science & Medicine on how positive psychosocial factors—such as resilience, self-efficacy, and emotional support—can reduce stress in people with systemic lupus erythematosus (SLE). In this episode, she speaks with Drs. Kimberly DeQuattro and Sarah Patterson about these factors' protective effects, even for those with trauma histor
Krill Oil may represent a promising complementary therapy in SLE
Join Dr. Anna Wloska from the Lupus foundation of America and Drs. Peter Lipsky and Amerie Grammer as they discuss the effectivenss of krill oil in reducing disease activity in systemic lupus erythematosus. In this episode, our guest highlight the potential therapeutic benefits of restoring omega-3 fatty acids in patients with SLE and the potency and efficacy of omegga-3s found in krill oil versus
Understanding the Critical Role of Lupus Clinical Trial Outcome Measures in Advancing Therapeutic Development
Join Dr. Anna Wolska from the Lupus Foundation of America and Dr. Laurent Arnaud, Professor of Rheumatology at the Department of Rheumatology, University Hospitals of Strasbourg as they discuss systemic lupus erythematosus (SLE) clinical trials. In this episode, Dr. Arnaud highlights the complexities of drug approval processes in lupus, the pivotal role of large-scale phase three randomized trials
Interpreting Hydroxychloroquine Blood Levels in Lupus
Join Dr. Anna Wolska from the Lupus Foundation of America as she delves into a groundbreaking discussion with Dr. Stephen Balevic focused on hydroxychloroquine blood levels and understanding medication adherence in lupus patients. In this episode, Dr. Balevic, a rheumatologist and clinical pharmacologist from Duke University, explains the nuances of interpreting hydroxychloroquine levels, the chal
Use of Artificial Intelligence and Machine Learning in Clinical Practice
Join Dr. Anna Wolska and Dr. May Choi as they explore the role of Artificial Intelligence (AI) and Machine Learning (ML) in guiding diagnostic and care decisions for systemic lupus erythematosus (SLE). Dr. Choi delves into key elements of machine learning and its potential impact on improving outcomes, particularly in underserved populations. She also discusses various types of machine learning, s
To RNase or Not to RNase: That Is the Question
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical
A decision-aid facilitates patient understanding of benefits vs. risk of hydroxychloriquine use as part of routine care for lupus
Dr. Anna Wolska engages in a conversation with Dr. Shivani Garg and Dr. Christie Bartels to delve into the development and implementation of HCQ-SAFE. This innovative decision-aid is designed to empower individuals living with lupus to engage in shared-decision making. The authors discuss the importance of streamlining and enhancing shared decision-making dynamics between patients and healthcare p
Dual dsDNA testing may be needed to fully understand patient disease status
Dr. Anna Wolska speaks to Dr. Michael Belmont and Devyn Zaminski to discuss the importance of dual dsDNA testing in order to full understand disease activity. In this study, they made the observation that there is a large amount of discordance in anti-dsDNA antibodies assays. Misinterpretation or errors in anti- dsDNA antibody testing could have negative implications on long term outcomes in peopl
Is Anifrolumab an effective treatment for lupus nephritis?
Dr. Anna Wolska engages in a discussion with renowned experts, Dr. Catharina Lindholm and Dr. David Jayne, to explore findings from the phase II TULIP Lupus Nephritis trial. This in-depth conversation centers on results from a clinical trial where they evaluated the efficacy of intensified anifrolumab treatment in individuals with active lupus nephritis.
Read the article: http://dx.doi.org/10.11
Which one is better at controlling lupus: Belimumab or Anifrolumab?
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic
Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to
Testing a new measure of lupus improvement that encompasses the patients’ perspectives and doctors’ evaluations
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Anca Askanase and Joan Merrill, the developers of the LFA-REAL tool. Together, they discuss the importance of using a tool like LFA-REAL to understand how clinician and patient reported outcomes are essential for understanding efficacy and effectiveness of experimental therapeutics developed to treat people living with lupus.
R
Understanding Lupus: Exploring the Differences between Type 1 and Type 2 Symptoms
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Amrie Grammer and Dr. Peter Lipsky from AMPEL BioSolutions. Together they describe the molecular endotypes of Type 1 and Type 2 Systemic Lupus Erythematosus. This episode uncovers the distinct molecular profiles of these SLE types and paves the way for personalized treatment approaches based on these classifications.
Link to pub
Unpacking Lupus Treatment: How Quickly Does Anifrolumab Start Working? Insights from TULIP Trials
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness
Biomarker reduction indicates treatment response to Belimumab
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and po
Mesenchymal stromal cells: a potential new SLE treatment option?
Duane Peters from the Lupus Foundation of America interviews Dr Gary Gilkeson from the Medical University of South Carolina about a phase I trial into the use of mesenchymal stromal cells (MSC) in refractory lupus patients in the USA, following impressive results of clinical improvement resulting from this therapy in China.
The trial indicated that infusions of MSCs derived from the umbilical cor
Using patient registries to estimate SLE incidence rate in the USA
Duane Peters from the Lupus Foundation of America interviews Dr Peter Izmirly from New York University and Dr Elizabeth Ferucci from the Alaska Native Tribal Health Consortium, both in the USA.
They discuss the establishment of a network of population-based lupus patient registries in the USA and how these have been used to estimate the incidence rate of systemic lupus erythematosus using standa
Defining remission in systemic lupus erythematosus
Duane Peters from the Lupus Foundation of America interviews Professor Ronald van Vollenhoven from the Amsterdam University Medical Centers in the Netherlands and Dr Cynthia Aranow from the Feinstein Institute for Medical Research in New York, USA.
They discuss the efforts of the DORIS international task force to agree on a single definition of remission in systemic lupus erythematosus, which th
What’s the relationship between self-efficacy and quality of life in SLE patients?
Duane Peters from the Lupus Foundation of America talks to Dr Cristina Drenkard from Emory University and Dr Teresa Brady from Clarity Consulting and Communications, both based in Atlanta, USA.
They discuss their paper on the relationship between levels of self-efficacy and health behaviours and outcomes in black women with SLE. Their study specifically evaluated the associations between age, ed
Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE
Duane Peters from the Lupus Foundation of America talks to Dr Sylvia Kamphuis and Dr Javad Wahadat from the Erasmus Medical Center in Rotterdam in the Netherlands about aiming for a Low Lupus Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE). They outline the difference between LLDAS and clinical remission (CR), and discuss how LLDAS may be a more achievable target
Could a high fiber diet positively impact the gut microbiome of SLE patients?
Duane Peters from the Lupus Foundation of America interviews Professor Iryna Kulyk from Indiana University in the USA and Professor Martin Kriegel from the University of Münster in Germany and Yale University in the USA. They discuss their study, presented at the Lupus 21st Century conference in September 2021, on the influence of the consumption of resistant starch (a type of dietary fiber) on th
A new biomarker for cognitive dysfunction in SLE?
Duane Peters from the Lupus Foundation of America interviews Dr Erik Anderson and Dr Meggan Mackay from the Feinstein Institutes for Medical Research in New York in the USA. They discuss their study into imbalances in quinolinic acid and kynurenic acid levels in the brain in SLE patients, and propose that the ratio between these two metabolites could be used as a new biomarker or therapeutic targe
Screening for cognitive dysfunction in SLE patients
Duane Peters from the Lupus Foundation of America interviews Jennifer He from the University of Western Ontario in Canada about her research into using neuropsychological battery tests to determine the degree of cognitive dysfunction in lupus patients. A high degree of variability in performance across multiple tests (a high dispersion score) is associated with a higher risk of cognitive dysfuncti
Highlights of ACR Convergence 2021
Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, about the highlights of ACR Convergence 2021, which was held virtually on 3-9 November (https://www.rheumatology.org/Annual-Meeting).
Personalised metabolite monitoring during pre-conception and pregnancy in SLE patients
Duane Peters from the Lupus Foundation of America interviews Francisca Lambert-Fliszar and Dr Evelyne Vinet from McGill University Health Centre in Canada. They discuss monitoring 6-mercaptopurine (6-MP) metabolite levels to enable personalisation of immunosuppressive therapies prior to conception or during pregnancy, in order to most effectively and safely control the disease during this critical
Can you predict lupus nephritis outcomes using machine learning models?
Duane Peters from the Lupus Foundation of America interviews Dr Jim Oates from the Medical University of South Carolina and Ralph H. Johnson VA Medical Center in Charleston, USA. They discuss his paper on developing risk prediction models in lupus nephritis to predict outcomes at the point of diagnosis, which can be used as a decision support tool to help inform treatment strategies for patients.
Highlights of the LUPUS & CORA 2021 joint congress
Duane Peters from the Lupus Foundation of America interviews Dr Ronald von Vollenhoven, one of LSM's Editors-in-Chief, about the highlights of the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) and the 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA). These events were held jointly as a virtual congress on 6-9 October 2021 (https://lupus
Identifying therapeutic targets in lupus nephritis: is obtaining research tissue via biopsy safe?
Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, and Dr Philip Carlucci from New York University in the USA, a previous recipient of the LFA's Gina M. Finzi Memorial Student Summer Fellowship. They discuss their recent paper on the safety of kidney biopsies in patients with SLE enrolled in the Accelerating Medicines Partnership in the USA,
LSM’s first Journal Impact Factor™
Duane Peters from the Lupus Foundation of America interviews the Lupus Science & Medicine Editors-in-Chief, Professor Jill Buyon and Professor Ronald van Vollenhoven. They discuss the recent release of LSM's first Journal Impact Factor™, explaining how it has been calculated, and what it means for the journal, its authors and readers.
Access all the LSM journal metrics: https://lupus.bmj.co
Can you conduct clinical trials on lupus patients in a home setting?
Duane Peters from the Lupus Foundation of America interviews Dr Stephen Balevic, Dr Rachel Randell and Professor Laura Schanberg from Duke University in the USA. They discuss the advantages and challenges of designing and implementing self-controlled clinical trials for paediatric lupus patients in a home setting, based on their experience of conducting the Individual Patient Exposure and Response
EULAR 2021 eCongress Highlights
Duane Peters of the Lupus Foundation of America follows up with Professor Ronald van Vollenhoven of the Amsterdam University Medical Centers to discuss the highlights of the lupus research presented at the EULAR 2021 eCongress, which was held virtually on 2-5 June 2021.
EULAR Congress website: https://congress.eular.org/index.cfm
EULAR 2021 abstracts: https://ard.bmj.com/content/80/Suppl_1
Safety profile of anifrolumab in SLE patients
Duane Peters from the Lupus Foundation of America interviews Professor Eric Morand from Monash University in Australia and Dr Raj Tummala from AstraZeneca in the USA about phase II and III trials of the human monoclonal antibody anifrolumab.
Their pooled analysis of data from the MUSE, TULIP-1 and TULIP-2 trials showed that, in addition to demonstrating efficacy in adults with moderate to severe
The ALPHA Project
Duane Peters from the Lupus Foundation of America interviews Dr Susan Manzi from the Allegheny Health Network and Kathleen Arntsen from the Lupus and Allied Diseases Association, both based in the USA, about the Addressing Lupus Pillars for Health Advancement (ALPHA) Project.
The ALPHA Project is the first global initiative to identify, prioritise and address top barriers in lupus impacting diag
Lupus Academy 10th Annual Meeting Highlights
Duane Peters of the Lupus Foundation of America follows up with Professor Ronald van Vollenhoven of the Amsterdam University Medical Centers to discuss the highlights of the 10th Annual Meeting of the Lupus Academy, which was held virtually on 16-18th April 2021.
Lupus Science & Medicine is the official journal of the Lupus Academy and the abstracts from the event have been published as a su
Lupus Academy Tenth Annual Meeting Preview
Duane Peters of the Lupus Foundation of America interviews Professor Ronald van Vollenhoven of the Amsterdam University Medical Centers about the 10th Annual Meeting of the Lupus Academy, which will be held virtually from 16-18th April 2021. As well as his role as co-Editor-in-Chief of Lupus Science & Medicine, Professor van Vollenhoven is a member of the Lupus Academy Steering Committee and h
Apolipoprotein L1 risk genotypes in Ghanaian patients
Duane Peters from the Lupus Foundation of America interviews Dr Ashira Blazer from New York University, USA, and Dr Ida Dzifa Dey from the University of Ghana in Accra, Ghana, about the associations between apolipoprotein L1 genetic polymorphisms and disease outcomes among SLE patients in Ghana.
Access the paper here: https://lupus.bmj.com/content/8/1/e000460
Anti-Müllerian hormone in African- American women with SLE
Duane Peters from the Lupus Foundation of America interviews Ms Meghan Angley and Dr Sam Lim from Emory University in Georgia, and Dr Megan Clowse from Duke University in North Carolina, about infertility and reproductive injustice in African-American women with systemic lupus erythematosus.
Access the papers here:
https://lupus.bmj.com/content/7/1/e000439
https://lupus.bmj.com/content/7/1/e00045
Efficacy and safety of rituximab biosimilar in refractory lupus
Duane Peters from the Lupus Foundation of America interviews Dr Pintip Ngamjanyaporn and Dr Nantakarn Pongtarakulpanit from Mahidol University in Bangkok, Thailand, about their study on the short term efficacy and safety of rituximab biosimilar in refractory lupus.
Access the paper here: https://lupus.bmj.com/content/7/1/e000442
Metabolic syndrome in SLE patients
Duane Peters from the Lupus Foundation of America interviews Dr Diane Apostolopoulos and Dr Eric Morand from Monash Health in Australia about their study into the prevalence of metabolic syndrome in patients with SLE and the potential associations between the use of glucocorticoids and specific cardiovascular risk factors.
Access the paper here: https://lupus.bmj.com/content/7/1/e000436
Validating the use of LFA-REAL to measure disease severity in SLE
Duane Peters from the Lupus Foundation of America interviews Dr Manuel Francisco Ugarte-Gil from Peru and Dr Joan Merrill and Dr Anca Askanase from the USA about their study evaluating the use of LFA-REAL clinician-reported and patient-reported outcomes in establishing disease severity in SLE.
Access the paper here: https://lupus.bmj.com/content/7/1/e000419
ANA testing in SLE and autoimmune rheumatic diseases
Duane Peters from the Lupus Foundation of America interviews Dr May Choi and Dr Peter Schur from the Lupus Program at Brigham and Women's Hospital in Boston. They discuss the use of the ANA assay for the diagnosis and classification of systemic lupus and other autoimmune rheumatic diseases.
Access the paper here: https://lupus.bmj.com/content/7/1/e000431
Kynurenine pathway is altered in patients with SLE and associated with severe fatigue
Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper: Kynurenine pathway is altered in patients with SLE and associated with severe fatigue.
Access the paper here: http://doi.org/10.1136/lupus-2017-000254
TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper:TNF-alpha and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus.
Access the paper here: http://doi.org/10.1136/lupus-2018-000260
Lupus Science & Medicine: what makes it special?
Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, Professor of Rheumatology at New York University School of Medicine and co-Editor-in-Chief of Lupus Science & Medicine. Dr Buyon presents an overview of the journal's strengths and unique features, the editorial review process, and why authors should consider submitting their next lupus paper to LSM.
Learn more about
Anifrolumab effects on rash and arthritis
Lupus Science & Medicine Associate Editor Professor Lars Ronnblom talks to Professor Joan T. Merrill from the Oklahoma Medical Research Foundation about her published paper: Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
Access the paper here: https://lupus.bmj.com/content/5/1
COVID-19 Impact on people with lupus
Dr Jill Buyon, co-Editor in Chief of Lupus, Science & Medicine, explores the lessons we're learning six months into the global pandemic and the impact this is having on lupus patients, the medical landscape, and the research publishing space.
Lupus, immunity and Covid-19 - Part 2
In the second part of a general update on the effects of Covid-19 in lupus patients, Sara Booth, University of Cambridge, talks to Dr Anca D Askanase, MD, MPH Director, Columbia University Lupus Center Associate Professor of Medicine Columbia University College of Physicians and Surgeons.
Listen to part one on your favourite podcast provider, including one of the links below:
https://soundcloud.co
Immunity for lupus patients and effects of Covid-19 - Part 1
In this podcast, Sara Booth, University of Cambridge, talks to Professor Sarah Rowlands (Florey Professor of Infection and Immunity,University of Sheffield and Honorary Consultant Physician Nuffield Department of Medicine, Oxford), who specialises in infectious diseases and has a special interest in immunity to viruses.
Listen to part two on your favourite podcast provider, including one of the li
Education and the latest in treatment: reporting from the Lupus Academy 2017
An insight into the important learnings of the Lupus Academy 2017 is brought to you in this special Lupus Science & Medicine podcast.
The Editor-in-Chief of the journal Ronald van Vollenhoven, a founding member of the Lupus Academy, spoke with several of the faculty and the delegates during the meeting held in Lisbon, Portugal, between the 5th and the 7th of May.
The Lupus Academy is a UK-ba
Lupus Science and Medicine first year anniversary
To mark the first anniversary of Lupus Science and Medicine Harriet Vickers speaks to Dr Ronald van Vollenhoven and Dr Jill Buyon about notable published papers, publishing without an impact factor and what to expect from the journal in the coming year.
BMJ and the Lupus Foundation of America announce the first open access lupus scientific journal
Sandra Raymond, president and CEO of the Lupus Foundation of America, talks about why the foundation wanted to create Lupus Science and Medicine, and what she hopes the journal will achieve.
For more information on the journal, see http://journals.bmj.com/site/lupus/index.html.
What to expect from Lupus Science and Medicine
The Lupus Foundation of America and BMJ are joining forces to publish Lupus Science and Medicine, the first open access lupus scientific journal.
Joint editor-in-chief Ronald van Vollenhoven, also head of the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institutet, discusses what readers and authors can expect from the journal.
To sign up for updates about the journal, go
